U.S. Markets open in 9 hrs 27 mins

[$$] Shire Investors Can Profit From Takeda Skepticism

with Shire are higher than the market currently thinks. The cash and stock deal will solve a major strategic problem for Takeda since drug sales in Japan are falling due to an aging population and fairly strict government regulations on drug prices. Shire books a majority of its sales in the U.S., where the long term industry outlook is brighter and pricing is more permissive.